Syros Pharmaceuticals, Inc. (SYRS) delivered a return of -98.97% over the past year. Since SYRS does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Syros Pharmaceuticals, Inc. one year ago would be worth $103 today, representing a loss of $9,897.

Syros Pharmaceuticals, Inc. (SYRS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For SYRS, the total return equals the price-only return.

No, Syros Pharmaceuticals, Inc. (SYRS) underperformed the S&P 500 by 130.29 percentage points over the past year. SYRS delivered a total return of -98.97%, compared to the S&P 500's 31.32%. This means a passive S&P 500 index fund outperformed SYRS by 130.29pp during this period.

Syros Pharmaceuticals, Inc. (SYRS) experienced a maximum drawdown of -99.75% over the past year, declining from its peak on 2025-05-09 to its trough on 2025-09-23. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Syros Pharmaceuticals, Inc. (SYRS)'s long-term returns with dividends reinvested. Over 10 years, the total return is -100.0% (-73.1% CAGR) — $10,000 would have grown to $0. Over 20 years: -100.0% total return (-48.1% CAGR) — $10,000 → $0. Over 30 years: -100.0% total return (-35.4% CAGR) — $10,000 → $0. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Syros Pharmaceuticals, Inc.'s best calendar year was 2023 with a total return of 120.1%. Its worst year was 2025 with a total return of -99.9%. This range shows the volatility investors should expect — the difference between the best and worst year is 219.9 percentage points.